1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,968 | 1,035 | 07:30 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Tevogen Bio Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | Tevogen files to sell 30.73M shares of common stock for holders | 2 | Seeking Alpha | ||
| 18.06. | Tevogen Bio Inc: Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery | 209 | GlobeNewswire (Europe) | WARREN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today provided an update on its ongoing development of a cytotoxic T lymphocyte (CTL)... ► Artikel lesen | |
| 09.06. | Tevogen Bio Inc: Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives | 2 | GlobeNewswire (USA) | ||
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 03.06. | Tevogen Bio erweitert Bürofläche in New Jersey durch wichtigen Nachtrag | 3 | Investing.com Deutsch | ||
| 03.06. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.05. | Tevogen Bio erweitert KI-Initiative in der Immuntherapie-Entwicklung | 5 | Investing.com Deutsch | ||
| 30.05. | Tevogen Bio expands AI in immunotherapy development | 1 | Investing.com | ||
| 30.05. | Tevogen Bio Inc: Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships | 4 | GlobeNewswire (USA) | ||
| 26.05. | Tevogen Peports Plans to Increase the Target Population for TVGN 489 | 2 | Insider Monkey | ||
| 23.05. | Tevogen expands target for COVID treatment to seniors | 1 | Investing.com | ||
| 23.05. | Tevogen erweitert Zielgruppe für COVID-Behandlung auf Senioren | 3 | Investing.com Deutsch | ||
| 23.05. | Tevogen Bio Inc: Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow | 127 | GlobeNewswire (Europe) | WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced a planned expansion of TVGN 489's target population to include patients... ► Artikel lesen | |
| 22.05. | Tevogen Bio Inc: Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting | 83 | GlobeNewswire (Europe) | WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced that it will provide several updates to stockholders in advance of... ► Artikel lesen | |
| 14.05. | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.05. | Tevogen Bio Inc: Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation | 117 | GlobeNewswire (Europe) | WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). As the biopharma industry faces increasing competition from international markets... ► Artikel lesen | |
| 01.05. | Tevogen Bio Holdings Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 30.04. | Tevogen Bio Inc: CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment | 74 | GlobeNewswire (Europe) | WARREN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that CD8 Technology Services LLC ("CD8") has signed a letter of intent... ► Artikel lesen | |
| 29.04. | Tevogen Bio shares surge on revenue forecast | 2 | Investing.com | ||
| 29.04. | Tevogen Bio-Aktien steigen nach Umsatzprognose | 3 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
88 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,130 | -0,59 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| AMGEN | 240,75 | +0,10 % | ROUNDUP/Aktien New York Schluss: Gewinne - 'Iran-Angriff eine Gesichtswahrung' | NEW YORK (dpa-AFX) - Der Nahost-Krieg hat am Montag die Richtung an den US-Börsen bestimmt. Die wichtigsten US-Indizes legten am Ende kräftig zu und erreichten kurz vor dem Handelsschluss Tageshöchststände.... ► Artikel lesen | |
| NOVAVAX | 5,536 | -0,34 % | Novavax Sees Sanofi Vaccine Pact as Model for Future Deals, Some Going Beyond Infectious Disease | ||
| PALATIN TECHNOLOGIES | 0,143 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 445,80 | -0,16 % | Sanofi und Regeneron erhalten weitere US-Zulassung für Dupixent | DJ Sanofi und Regeneron erhalten weitere US-Zulassung für Dupixent
Von Adria Calatayud
DOW JONES--Sanofi und ihr Partner Regeneron Pharmaceuticals können ihren Entzündungshemmer Dupixent in... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,800 | -4,76 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,700 | 0,00 % | COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders | Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 46,690 | +0,54 % | BioMarin Presents Long-term Efficacy And Safety Of Roctavian | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) Tuesday announced new data underscoring the long-term efficacy and safety of Roctavian (valoctocogene roxaparvovec-rvox).The Phase... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,421 | -2,55 % | Biotech-Pick: Warum sie diese Aktie unbedingt auf dem Zettel haben sollten! | ||
| ARROWHEAD PHARMACEUTICALS | 13,420 | -0,07 % | Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results | PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting... ► Artikel lesen | |
| XOMA ROYALTY | 23,400 | -0,85 % | XOMA Royalty Corporation: XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements | Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareholder... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,094 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,170 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort | -Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. -... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report |
TEVOGEN BIO HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.